Genedx Holdings Corp. has announced the publication of new data from the SeqFirst study in The Journal of Pediatrics, demonstrating the benefits of rapid genomic testing as a first-tier test for non-critical care pediatric inpatients. The study, conducted in collaboration with Seattle Children's clinical genetics team, showed that implementing rapid exome sequencing (rES) and rapid genome sequencing (rGS) significantly reduced the time to achieve a precise genetic diagnosis from nearly ten months to 13 days. The data supports the broader adoption of rapid genomic testing in non-critical care settings, suggesting improvements in pediatric patient outcomes and potential reductions in healthcare costs. The study results indicate that rapid genomic testing yields a diagnostic rate over 42%, comparable to critical care settings, and highlight the ability of healthcare providers to effectively identify appropriate candidates for genetic testing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.